Day: August 15, 2023
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six months ended June 30, 2023.
Financial Results for the Six Months Ended June 30, 2023
Net Loss: The net loss attributable to common stockholders was $3.18 million, from operations, or a basic and diluted loss per share of $(0.13). For the same period in 2022, loss from operations was $2.45 million, or a basic and diluted loss per share attributable to common stockholders of ($0.35)
Cash Position: The Company had $40,458 in cash and...
Salona Global Posts Second Quarter Results and Provides Update on Turn Around Plan
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona Global” or the “Company”) (TSXV:SGMD) today posted financial results for the second quarter of 2023, ending June 30, 2023, and provided an update on its turn-around plan.
During the second quarter, the Company acquired Biodex Medical Systems, Inc. (“Biodex”), pushing revenue to $16.6 million for the three months ended June 30, 2023. The Company reported negative Adjusted EBITDA (defined below) of $819,394 for the same period.
On June 13, 2023, Michael Seckler was appointed CEO of the Company by the board of directors with a mandate to generate organic revenue growth and achieve enterprise profitability. In the time since his appointment Mr. Seckler has taken several steps to achieve this goal including:Operating expense reduction of...